Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
Provided By GlobeNewswire
Last update: Oct 3, 2024
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce its participation in the upcoming scientific conferences:
